Universidad de Burgos RIUBU Principal Default Universidad de Burgos RIUBU Principal Default
  • español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
Universidad de Burgos RIUBU Principal Default
  • Ayuda
  • Contacto
  • Sugerencias
  • Acceso abierto
    • Archivar en RIUBU
    • Acuerdos editoriales para la publicación en acceso abierto
    • Controla tus derechos, facilita el acceso abierto
    • Sobre el acceso abierto y la UBU
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo RIUBUComunidadesFechaAutor / DirectorTítuloMateria / AsignaturaEsta colecciónFechaAutor / DirectorTítuloMateria / Asignatura

    Mi cuenta

    AccederRegistro

    Estadísticas

    Ver Estadísticas de uso

    Compartir

    Ver ítem 
    •   RIUBU Principal
    • E-Prints y Datos de investigación
    • Grupos de investigación
    • One Health Microbiology (OHM)
    • Artículos OHM
    • Ver ítem
    •   RIUBU Principal
    • E-Prints y Datos de investigación
    • Grupos de investigación
    • One Health Microbiology (OHM)
    • Artículos OHM
    • Ver ítem

    Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10259/7632

    Título
    Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants
    Autor
    Simões, Rachel Siqueira de Queiroz
    Rodríguez Lázaro, DavidAutoridad UBU Orcid
    Publicado en
    International Journal of Environmental Research and Public Health. 2022, V. 19, n. 4, 2392
    Editorial
    MDPI
    Fecha de publicación
    2022-02
    DOI
    10.3390/ijerph19042392
    Resumen
    Several coronaviruses (CoVs) have been identified as human pathogens, including the α-CoVs strains HCoV-229E and HCoV-NL63 and the β-CoVs strains HCoV-HKU1 and HCoV-OC43. SARS-CoV, MERS-CoV, and SARS-CoV-2 are also classified as β-coronavirus. New SARS-CoV-2 spike genomic variants are responsible for human-to-human and interspecies transmissibility, consequences of adaptations of strains from animals to humans. The receptor-binding domain (RBD) of SARS-CoV-2 binds to receptor ACE2 in humans and animal species with high affinity, suggesting there have been adaptive genomic variants. New genomic variants including the incorporation, replacement, or deletion of the amino acids at a variety of positions in the S protein have been documented and are associated with the emergence of new strains adapted to different hosts. Interactions between mutated residues and RBD have been demonstrated by structural modelling of variants including D614G, B.1.1.7, B1.351, P.1, P2; other genomic variants allow escape from antibodies generated by vaccines. Epidemiological and molecular tools are being used for real-time tracking of pathogen evolution and particularly new SARS-CoV-2 variants. COVID-19 vaccines obtained from classical and next-generation vaccine production platforms have entered clinicals trials. Biotechnology strategies of the first generation (attenuated and inactivated virus–CoronaVac, CoVaxin; BBIBP-CorV), second generation (replicating-incompetent vector vaccines–ChAdOx-1; Ad5-nCoV; Sputnik V; JNJ-78436735 vaccine-replicating-competent vector, protein subunits, virus-like particles–NVX-CoV2373 vaccine), and third generation (nucleic-acid vaccines–INO-4800 (DNA); mRNA-1273 and BNT 162b (RNA vaccines) have been used. Additionally, dendritic cells (LV-SMENP-DC) and artificial antigenpresenting (aAPC) cells modified with lentiviral vector have also been developed to inhibit viral activity. Recombinant vaccines against COVID-19 are continuously being applied, and new clinical trials have been tested by interchangeability studies of viral vaccines developed by classical and next-generation platforms.
    Palabras clave
    Genomic variants
    Technological platforms
    SARS-CoV-2
    Materia
    Microbiología
    Microbiology
    Enfermedades infecciosas
    Communicable diseases
    URI
    http://hdl.handle.net/10259/7632
    Versión del editor
    https://doi.org/10.3390/ijerph19042392
    Aparece en las colecciones
    • Artículos OHM
    Atribución 4.0 Internacional
    Documento(s) sujeto(s) a una licencia Creative Commons Atribución 4.0 Internacional
    Ficheros en este ítem
    Nombre:
    Simões-ijerph_2022.pdf
    Tamaño:
    1.844Mb
    Formato:
    Adobe PDF
    Thumbnail
    Visualizar/Abrir

    Métricas

    Citas

    Academic Search
    Ver estadísticas de uso

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis
    Mostrar el registro completo del ítem